Novartis (NVS)
(Delayed Data from NYSE)
$97.28 USD
+2.16 (2.27%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $97.31 +0.03 (0.03%) 6:14 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Novartis (NVS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$116.60 | $125.00 | $109.00 | 22.58% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Novartis comes to $116.60. The forecasts range from a low of $109.00 to a high of $125.00. The average price target represents an increase of 22.58% from the last closing price of $95.12.
Analyst Price Targets (5 )
Broker Rating
Novartis currently has an average brokerage recommendation (ABR) of 2.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 2.45 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, three are Strong Buy, representing 27.27% of all recommendations. A month ago, Strong Buy represented 27.27%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.45 | 2.45 | 2.45 | 2.45 | 2.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/23/2024 | BMO Capital Markets | Etzer Darout | Not Available | Hold |
10/24/2023 | Not Identified | Not Identified | Hold | Hold |
9/4/2023 | Berenberg Bank | Kerry Holford | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.45 |
ABR (Last week) | 2.45 |
# of Recs in ABR | 11 |
Average Target Price | $116.60 |
LT Growth Rate | 8.60% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 199 of 252 |
Current Quarter EPS Est: | 1.73 |